KITLG and prostate cancer: Recent work in prostate cancer identified that PKD2 or PKD3 knockdown results in decreased expression and secretion of pro-inflammatory chemokines SCF, CCL5 and CCL11 in two prostate cancer cell lines, with the proteins contributing to the chemotactic migration of mast cells in vitro.81